Monday, September 28, 2015
Cynvenio Partners With Korea's ATGen Global
Los Angeles-based cancere diagnostics technology developer Cynvenio and Korean biotech ATGen Global announced this morning that they are in a strategic partnership, which will bring a test developed by ATGen Global to the U.S. Market. Financial details of the deal were not announced. The two said that they will bring ATGen's NK Vue test, which measures what it calls the "Natural Killer (NK) cell activity" in blood--a measure of the immune system--to the U.S., to help identify patients who have an increased risk of cancer and autoimmune diseases. NK Vue's technology is being tested for monitoring different cancer types, including breast, prostate, lung, colorectal, ovarian, and gastric cancers.